Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioVie Inc. stock logo
BIVI
BioVie
$1.54
-4.0%		$1.68
$0.82
▼
$3.79
$13.56M0.74442,216 shs182,525 shs
HIND
Vyome
$2.03
-0.5%		$2.13
$1.75
▼
$6.56
$14.32M1.520,503 shs5,143 shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$5.10
-26.6%		$8.75
$4.93
▼
$26.64
$13.18M1.625,350 shs61,418 shs
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
$0.20
$0.43
$0.20
▼
$1.23
$3.44M0.92808,608 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioVie Inc. stock logo
BIVI
BioVie
0.00%-0.31%-25.69%-20.15%-13.71%
HIND
Vyome
0.00%-2.86%-7.27%-4.23%-60.54%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
0.00%+9.45%-17.34%-51.05%-71.98%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00%0.00%0.00%0.00%+11.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioVie Inc. stock logo
BIVI
BioVie
$1.54
-4.0%		$1.68
$0.82
▼
$3.79
$13.56M0.74442,216 shs182,525 shs
HIND
Vyome
$2.03
-0.5%		$2.13
$1.75
▼
$6.56
$14.32M1.520,503 shs5,143 shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$5.10
-26.6%		$8.75
$4.93
▼
$26.64
$13.18M1.625,350 shs61,418 shs
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
$0.20
$0.43
$0.20
▼
$1.23
$3.44M0.92808,608 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioVie Inc. stock logo
BIVI
BioVie
0.00%-0.31%-25.69%-20.15%-13.71%
HIND
Vyome
0.00%-2.86%-7.27%-4.23%-60.54%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
0.00%+9.45%-17.34%-51.05%-71.98%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00%0.00%0.00%0.00%+11.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioVie Inc. stock logo
BIVI
BioVie
1.00
SellN/AN/A
HIND
Vyome
2.50
Moderate Buy$9.25355.67% Upside
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
2.67
Moderate Buy$170.003,233.33% Upside
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest UBX, BIVI, HIND, and NRSN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
HIND
Vyome
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$3.50
9/3/2026
HIND
Vyome
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$3.50
9/3/2026
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
7/30/2026
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/29/2026
HIND
Vyome
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
BioVie Inc. stock logo
BIVI
BioVie
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$1.36 per shareN/A
HIND
Vyome
$320K44.53N/AN/A$0.67 per share3.03
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/A($0.96) per shareN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/A$0.39 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioVie Inc. stock logo
BIVI
BioVie
-$22.07M-$3.15N/AN/AN/AN/A-126.02%-108.88%11/9/2026 (Estimated)
HIND
Vyome
-$10.26M-$3.37N/AN/AN/A-3,024.84%-197.33%-138.14%N/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-$11.12M-$10.80N/AN/AN/AN/AN/AN/A12/2/2026 (Estimated)
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
-$25.99M-$1.62N/AN/AN/AN/A-246.82%-58.81%N/A

Latest UBX, BIVI, HIND, and NRSN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/25/2026Q2 2026
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/A-$1.05N/A-$1.05N/AN/A
8/12/2026Q4 2026
BioVie Inc. stock logo
BIVI
BioVie
-$0.52-$0.70-$0.18-$0.70N/AN/A
8/12/2026Q2 2026
HIND
Vyome
N/A-$0.10N/A-$0.10N/A$0.27 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
HIND
Vyome
N/AN/AN/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/AN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioVie Inc. stock logo
BIVI
BioVie
N/A
3.59
3.59
HIND
Vyome
N/A
4.37
4.37
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/A
0.31
0.31
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/A
1.95
1.95

Institutional Ownership

CompanyInstitutional Ownership
BioVie Inc. stock logo
BIVI
BioVie
4.59%
HIND
Vyome
22.06%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1.04%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
29.49%

Insider Ownership

CompanyInsider Ownership
BioVie Inc. stock logo
BIVI
BioVie
0.90%
HIND
Vyome
33.00%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
27.40%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
5.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioVie Inc. stock logo
BIVI
BioVie
138.45 million8.38 millionNo Data
HIND
Vyome
187.02 million4.70 millionN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
161.90 million1.38 millionNot Optionable
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
6017.21 million16.21 millionOptionable

Recent News About These Companies

Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice
June 30, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/unity-stock-crashes-nearly-50-223255215.html
Unity Biotechnology stock plunges after Nasdaq delisting notice
June 30, 2025  |  za.investing.comhttps://za.investing.com/news/stock-market-news/unity-biotechnology-stock-plunges-after-nasdaq-delisting-notice-93CH-3774321
Unity Biotechnology Inc News (UBX) - Investing.com
June 26, 2025  |  investing.comhttps://www.investing.com/equities/unity-biotechnology-inc-news
UBX Unity Biotechnology, Inc. - Seeking Alpha
June 24, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/UBX
HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)
May 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/hc-wainwright-co-downgrades-unity-biotechnology-ubx/ar-AA1FAA9z
Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities
May 18, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/UBX/pressreleases/32453730/unity-biotechnology-ubx-was-downgraded-to-a-hold-rating-at-mizuho-securities/
Bay Area biotech company Unity lays off every single worker, including CEO
May 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/bay-area-biotech-company-unity-once-worth-700m-lays-off-entire-remaining-workforce/ar-AA1EdgUy
Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce
May 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/bay-area-biotech-company-unity-once-worth-700m-lays-off-entire-remaining-workforce/ar-AA1EdgUy
South San Francisco biotech company lays off entire workforce, including CEO
May 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/biotech-company-once-valued-at-700-million-slashes-entire-workforce/ar-AA1EdIpE
Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles
May 5, 2025  |  fiercebiotech.comF
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
May 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/01/3072287/0/en/unity-biotechnology-to-present-at-the-arvo-2025-annual-meeting.html
NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325
April 25, 2025  |  ophthalmologytimes.comO
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
April 22, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/22/3065923/0/en/unity-biotechnology-inc-reports-first-quarter-2025-financial-results-and-business-updates.html
Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright
March 26, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-price-target-lowered-to-4-from-8-at-h-c-wainwright-1034514135
Unity Biotechnology price target lowered to $4 from $6 at Chardan
March 26, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-price-target-lowered-to-4-from-6-at-chardan-1034514054
Unity Biotechnology announces results from ASPIRE Phase 2b study in DME
March 25, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-announces-results-from-aspire-phase-2b-study-in-dme-1034508884
Unity reports topline outcomes from trial of diabetic macular oedema therapy
March 25, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/unity-reports-topline-outcomes-from-trial-of-diabetic-macular-oedema-therapy/ar-AA1BDWQO
UNITY Biotechnology tanks on mixed results for eye disease drug
March 25, 2025  |  thepharmaletter.comT
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
March 25, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2434950/ubx-stock-down-29-on-mixed-results-from-phase-ii-eye-disease-study?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2434950
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema
March 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/unity-biotechnology-shares-drop-33-153658881.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
J.M. Smucker logo card on a table with jam, peanut butter, coffee, strawberries, and toast.
J.M. Smucker Stock's Rally Has More Than Tariffs Behind It
By Chris Markoch | September 2, 2026
A Generac home standby generator installed outside a residential house at dusk, connected to an electrical panel.
Generac Plugs Into Amazon for an $8B AI-Powered Deal
By Jeffrey Neal Johnson | September 18, 2026
Vertiv logo displayed in a data center aisle lined with server racks and power equipment.
Vertiv’s UIG Deal Targets the Next Big Constraint in AI Data Centers
By Chris Markoch | September 4, 2026
Fabrinet, Dycom and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked Down
Fabrinet, Dycom, and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked Down
By Bridget Bennett | September 14, 2026
Digital illustration of a data center control room with monitors, cloud icons, and small robots linked by network graphics.
These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
By Chris Markoch | September 19, 2026
BioVie stock logo

BioVie NASDAQ:BIVI

$1.54 -0.07 (-4.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.59 +0.05 (+3.25%)
As of 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Vyome NASDAQ:HIND

$2.03 -0.01 (-0.49%)
Closing price 04:00 PM Eastern
Extended Trading
$2.02 0.00 (-0.25%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

NeuroSense Therapeutics stock logo

NeuroSense Therapeutics NASDAQ:NRSN

$5.10 -1.85 (-26.62%)
Closing price 03:59 PM Eastern
Extended Trading
$5.03 -0.07 (-1.37%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

UNITY Biotechnology stock logo

UNITY Biotechnology NASDAQ:UBX

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas